
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis</strong></summary>
            <div>
                <ul><li>- Journal: Gastroenterology</li><li>- Publication Year: 2025</li><li>- This Network Meta-Analysis (NMA) informs the 2025 update to the AGA Guidelines for moderate-to-severe Crohn's disease (CD).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- 1. In <b>biologic-exposed</b> patients, which two drug classes showed a likely important benefit over ustekinumab for maintenance therapy in treat-through trials?</li><li>- 2. Which drug class demonstrated significantly lower efficacy in patients with <b>ileal CD</b> compared to those with isolated colonic disease?</li><li>- 3. In the re-randomization maintenance trials, which drug and dose ranked highest for maintaining clinical remission among initial responders?</li><li>- 4. What was the pooled placebo rate for inducing clinical remission in <b>biologic-naïve</b> patients?</li><li>- 5. What key structural feature is absent in certolizumab pegol compared to infliximab and adalimumab, potentially affecting its mechanism of action?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Background & Study Rationale</strong></summary>
            <div>
                <ul><li>- Crohn's disease (CD) affects over <q>1 million</q> individuals in the U.S.</li><li>- Approximately <u>50%</u> of patients require hospitalization or surgery.</li><li>- A growing number of advanced therapies (5 mechanisms, 9 drugs) necessitates guidance on positioning and sequencing.</li><li>- Head-to-head trials are sparse, making network meta-analyses (NMAs) crucial for comparing efficacy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Methods & Key Definitions</strong></summary>
            <div>
                <ul><li>- <b>Population</b>: Adults with moderately-to-severely active CD.</li><li>- <b>Definition of Active Disease</b>: Crohn’s Disease Activity Index (CDAI) score of <q>220–450</q>.</li></ul>
                
        <details>
            <summary><strong>Key Outcomes Measured</strong></summary>
            <div>
                <ul><li>- <b><u>Critical Outcome</u></b>: Induction & Maintenance of <b>Clinical Remission</b>.</li><li>- Definition: CDAI score <q><150</q>.</li><li>- <b><u>Important Outcome</u></b>: Induction & Maintenance of <b>Clinical Response</b>.</li><li>- Definition: <q>100-point decrease</q> in CDAI from baseline.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinically Meaningful Difference (CMD)</strong></summary>
            <div>
                <ul><li>- A difference between two agents was considered 'important' if the absolute risk difference was <q>>50 per 1000 patients treated (5%)</q>.</li><li>- Differences between 0 and 5% were considered 'trivial'.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Assumed Placebo Rates</strong></summary>
            <div>
                <ul><li>- Calculated by meta-analysis of placebo arms from included trials.</li><li>- <b>Biologic-Naïve Patients</b>: <q>19%</q> for induction of clinical remission.</li><li>- <b>Biologic-Exposed Patients</b>: <q>14%</q> for induction of clinical remission.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Maintenance Trial Designs</strong></summary>
            <div>
                <ul><li>- <b>Treat-through trials</b>: Patients randomized to active or placebo and followed through induction and maintenance.</li><li>- <b>Responder re-randomization trials</b>: Only patients responding to induction are re-randomized for the maintenance phase.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Induction Therapy Efficacy</strong></summary>
            <div>
                <ul><li>- Analysis of 28 trials for induction therapy.</li><li>- Stratified by prior biologic exposure status.</li></ul>
                
        <details>
            <summary><strong><b>Biologic-Naïve Patients</b></strong></summary>
            <div>
                <ul><li>- Pooled placebo rate for clinical remission: <q>19%</q>.</li></ul>
                
        <details>
            <summary><strong><u>Clinical Remission</u></strong></summary>
            <div>
                <ul><li>- Most advanced therapies are effective compared to no treatment.</li></ul>
                
        <details>
            <summary><strong>Efficacy vs. Placebo (Direct Evidence)</strong></summary>
            <div>
                <ul><li>- <b>Moderate-to-high certainty evidence</b> for: <u>infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab</u>.</li><li>- <b>Low certainty evidence</b> for: <u>certolizumab pegol, upadacitinib</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Comparative Efficacy (Active Comparators)</strong></summary>
            <div>
                <ul><li>- <b>Adalimumab & Ustekinumab</b> vs. <b>Certolizumab pegol</b>:</li><li>- Showed an <u>important benefit</u> (moderate-to-high certainty).</li><li>- <b>Adalimumab & Ustekinumab</b> vs. <b>Upadacitinib</b>:</li><li>- Showed a <u>likely important benefit</u> (moderate certainty).</li><li>- <b>Vedolizumab, Risankizumab, Mirikizumab, Guselkumab</b> vs. <b>Certolizumab pegol</b>:</li><li>- Showed a <u>possible important benefit</u> (low certainty).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Drug Ranking (P-score)</strong></summary>
            <div>
                <ul><li>- 1. <b>Adalimumab</b> (P-score: <q>0.83</q>)</li><li>- 2. <b>Ustekinumab</b> (P-score: <q>0.70</q>)</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anticipated Remission Rates (at 19% placebo rate)</strong></summary>
            <div>
                <ul><li>- Adalimumab: <q>48%</q></li><li>- Ustekinumab / Vedolizumab: <q>43%</q></li><li>- Infliximab: <q>42%</q></li><li>- Guselkumab: <q>41%</q></li><li>- Mirikizumab: <q>40%</q></li><li>- Risankizumab: <q>38%</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><u>Clinical Response</u></strong></summary>
            <div>
                <ul><li>- Findings were broadly consistent with clinical remission data.</li><li>- Top ranked agents: <b>Infliximab</b> (P-score: <q>0.98</q>), <b>Adalimumab</b> (P-score: <q>0.78</q>), <b>Ustekinumab</b> (P-score: <q>0.75</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Biologic-Exposed Patients</b></strong></summary>
            <div>
                <ul><li>- Pooled placebo rate for clinical remission: <q>14%</q>.</li><li>- Prior exposure was predominantly to TNF antagonists.</li></ul>
                
        <details>
            <summary><strong><u>Clinical Remission</u></strong></summary>
            <div>
                <ul><li>- Efficacy varies more significantly in this population.</li></ul>
                
        <details>
            <summary><strong>Efficacy vs. Placebo (Direct Evidence)</strong></summary>
            <div>
                <ul><li>- <b>Moderate-to-high certainty evidence</b> for: <u>adalimumab, ustekinumab, risankizumab, guselkumab, upadacitinib</u>.</li><li>- <b>Low certainty evidence</b> for: <u>vedolizumab, mirikizumab</u>.</li></ul>
                
        <details>
            <summary><strong>Note on Adalimumab Data</strong></summary>
            <div>
                <ul><li>- Trial only included patients with prior <u>intolerance</u> or <u>secondary loss of response</u> to infliximab.</li><li>- Patients with primary nonresponse to infliximab were <u>excluded</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Comparative Efficacy (Active Comparators)</strong></summary>
            <div>
                <ul><li>- <b>Adalimumab, Risankizumab, Guselkumab</b> vs. <b>Vedolizumab</b>:</li><li>- <u>Likely important benefit</u> (moderate certainty).</li><li>- <b>Risankizumab & Guselkumab</b> vs. <b>Ustekinumab</b>:</li><li>- <u>Likely important benefit</u> (moderate certainty).</li><li>- <b>Adalimumab, Risankizumab, Upadacitinib</b> vs. <b>Mirikizumab</b>:</li><li>- <u>Possible important benefit</u> (low certainty).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Drug Ranking (P-score)</strong></summary>
            <div>
                <ul><li>- 1. <b>Adalimumab</b> (P-score: <q>0.87</q>)</li><li>- 2. <b>Guselkumab</b> (P-score: <q>0.82</q>)</li><li>- 3. <b>Risankizumab</b> (P-score: <q>0.71</q>)</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anticipated Remission Rates (at 14% placebo rate)</strong></summary>
            <div>
                <ul><li>- Adalimumab: <q>42%</q></li><li>- Guselkumab: <q>36%</q></li><li>- Risankizumab: <q>33%</q></li><li>- Upadacitinib: <q>30%</q></li><li>- Ustekinumab: <q>27%</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><u>Clinical Response</u></strong></summary>
            <div>
                <ul><li>- Findings consistent with remission data.</li><li>- Top ranked agents: <b>Guselkumab</b> (P-score: <q>0.95</q>) and <b>Risankizumab</b> (P-score: <q>0.81</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Maintenance Therapy Efficacy</strong></summary>
            <div>
                <ul><li>- Analysis of 22 trials for maintenance therapy.</li><li>- Analyzed separately by trial design.</li></ul>
                
        <details>
            <summary><strong><b>Treat-Through Design (at 1 year)</b></strong></summary>
            <div>
                <ul><li>- Patients randomized at baseline and followed for 48-52 weeks.</li></ul>
                
        <details>
            <summary><strong>Biologic-Naïve Patients</strong></summary>
            <div>
                <ul><li>- The benefit of any specific intervention over another was <b><u>uncertain</u></b>.</li><li>- Top ranked agents: <b>Guselkumab</b> 200mg q4w (P-score: <q>0.74</q>), <b>Mirikizumab</b> (P-score: <q>0.72</q>), <b>Ustekinumab</b> (P-score: <q>0.68</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Biologic-Exposed Patients</strong></summary>
            <div>
                <ul><li>- <b>Risankizumab & Guselkumab</b> ---> <u>important benefit</u> vs. <b>Ustekinumab</b> (moderate-to-high certainty).</li><li>- <b>Mirikizumab</b> ---> <u>possible benefit</u> vs. <b>Ustekinumab</b> (low certainty).</li><li>- Top ranked agents: <b>Risankizumab</b> (P-score: <q>0.96</q>), <b>Guselkumab</b> 200mg q4w (P-score: <q>0.74</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Re-randomization of Responders</b></strong></summary>
            <div>
                <ul><li>- Only patients who responded to induction therapy were included for maintenance analysis.</li></ul>
                
        <details>
            <summary><strong>Key Comparisons</strong></summary>
            <div>
                <ul><li>- <b>Adalimumab</b> showed higher rates of remission vs. <b>Vedolizumab</b> and <b>Risankizumab</b> (moderate-to-high certainty).</li><li>- <b>Upadacitinib 30mg daily</b> showed higher rates of remission vs. <b>Certolizumab pegol, Vedolizumab, Ustekinumab, and Risankizumab</b> (moderate-to-high certainty).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Drug Ranking (P-score)</strong></summary>
            <div>
                <ul><li>- 1. <b>Upadacitinib 30mg daily</b> (P-score: <q>0.94</q>)</li><li>- 2. <b>Adalimumab</b> (P-score: <q>0.85</q>)</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Safety Endpoints</strong></summary>
            <div>
                <ul><li>- Regulatory trials are generally not powered to detect significant differences in safety.</li></ul>
                
        <details>
            <summary><strong>Serious Adverse Events (SAEs)</strong></summary>
            <div>
                <ul><li>- In maintenance trials, risk of SAEs was <u>lower</u> with <b>Guselkumab 200mg q4w</b> compared with:</li><li>- Infliximab</li><li>- Vedolizumab</li><li>- Ustekinumab</li><li>- Guselkumab 100mg q8w</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Serious Infections</strong></summary>
            <div>
                <ul><li>- Risk of serious infections was <b><u>comparable</u></b> between all active interventions and placebo.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Discussion & Key Clinical Implications</strong></summary>
            <div>
                <ul><li>- This NMA provides crucial insights for positioning therapies in moderate-to-severe CD.</li></ul>
                
        <details>
            <summary><strong>Impact of Prior Biologic Exposure</strong></summary>
            <div>
                <ul><li>- Prior treatment exposure is a key determinant of subsequent therapy selection.</li></ul>
                
        <details>
            <summary><strong>Lymphocyte Trafficking Inhibitors (Vedolizumab)</strong></summary>
            <div>
                <ul><li>- May be <u>more efficacious</u> in <b>biologic-naïve</b> patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>JAK Inhibitors (Upadacitinib)</strong></summary>
            <div>
                <ul><li>- May be <u>more efficacious</u> in patients with prior <b>TNF antagonist exposure</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IL-23p19 Antagonists (Risankizumab, Guselkumab)</strong></summary>
            <div>
                <ul><li>- More effective than Ustekinumab (IL-12/23) primarily in patients with prior <b>TNF antagonist exposure</b>.</li></ul>
                
        <details>
            <summary><strong>Biological Rationale</strong></summary>
            <div>
                <ul><li>- Chronic inflammation in later-stage disease may be more dependent on <q>IL-23</q> than IL-12.</li><li>- T-cells from TNF-refractory patients show up-regulation of the <q>IL-23 receptor</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Impact of Disease Location</strong></summary>
            <div>
                <ul><li>- Efficacy of some therapies differs based on the location of inflammation.</li></ul>
                
        <details>
            <summary><strong>JAK Inhibitors (Upadacitinib)</strong></summary>
            <div>
                <ul><li>- Showed <u>strikingly lower efficacy</u> in patients with <b>ileal CD</b>.</li><li>- Pivotal trials showed no significant efficacy signal in ileal disease.</li><li>- A separate meta-analysis confirmed efficacy was observed <u>only</u> in patients with <b>isolated colonic disease</b> (OR <q>4.37</q>) but not ileal disease (OR <q>1.01</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Agents</strong></summary>
            <div>
                <ul><li>- <b>IL-23p19 and IL-12/23p40 antagonists</b> demonstrated efficacy in both colonic (OR <q>4.29</q>) and ileal disease (OR <q>2.31</q>).</li><li>- <b>Lymphocyte trafficking inhibitors</b> had comparable, though low, efficacy in both colonic (OR <q>1.79</q>) and ileal disease (OR <q>2.01</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Within-Class Differences in Efficacy</strong></summary>
            <div>
                <ul><li>- Efficacy can vary even among drugs with the same mechanism of action.</li></ul>
                
        <details>
            <summary><strong>TNF Antagonists</strong></summary>
            <div>
                <ul><li>- <b>Adalimumab</b> was more effective than <b>Certolizumab pegol</b> in biologic-naïve patients.</li><li>- <u>Potential Reason</u>: Certolizumab pegol lacks the <q>IgG1-Fc portion</q>, preventing complement-mediated and antibody-mediated cell-dependent cytotoxicity.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IL-23p19 Antagonists</strong></summary>
            <div>
                <ul><li>- <b>Risankizumab</b> may be more effective than <b>Mirikizumab</b> for inducing remission in biologic-exposed patients.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations & Incoherence</strong></summary>
            <div>
                <ul><li>- <b>Dosing</b>: Analysis used FDA-approved doses; real-world dose optimization may alter effectiveness.</li><li>- <b>Prior Exposure Complexity</b>: 'Biologic-exposed' is becoming more nuanced than just TNF-failure.</li><li>- <b>Outcomes</b>: Focused on clinical remission, not endoscopic outcomes, which were not consistently reported in older trials.</li></ul>
                
        <details>
            <summary><strong>Statistical Incoherence Example</strong></summary>
            <div>
                <ul><li>- For <b>Risankizumab vs. Ustekinumab</b> in biologic-exposed patients:</li><li>- <u>Direct evidence</u> (SEQUENCE trial) showed benefit: RR <q>1.47</q>.</li><li>- <u>Indirect evidence</u> suggested no benefit: RR <q>0.82</q>.</li><li>- The analysis relied on the head-to-head trial evidence in this case.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
